Pictet Asset Management Holding SA Buys 17,175 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)

Pictet Asset Management Holding SA grew its stake in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 1.5% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,183,682 shares of the biotechnology company's stock after buying an additional 17,175 shares during the period. Pictet Asset Management Holding SA owned approximately 1.86% of Blueprint Medicines worth $103,241,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the stock. Torray Investment Partners LLC grew its stake in Blueprint Medicines by 1.1% in the 4th quarter. Torray Investment Partners LLC now owns 16,499 shares of the biotechnology company's stock valued at $1,439,000 after buying an additional 186 shares during the last quarter. Franklin Resources Inc. grew its position in shares of Blueprint Medicines by 0.7% in the third quarter. Franklin Resources Inc. now owns 36,761 shares of the biotechnology company's stock valued at $3,259,000 after purchasing an additional 265 shares during the last quarter. Hillsdale Investment Management Inc. grew its position in shares of Blueprint Medicines by 0.6% in the fourth quarter. Hillsdale Investment Management Inc. now owns 50,830 shares of the biotechnology company's stock valued at $4,433,000 after purchasing an additional 310 shares during the last quarter. Quarry LP acquired a new position in shares of Blueprint Medicines during the 3rd quarter worth about $32,000. Finally, Van ECK Associates Corp lifted its position in shares of Blueprint Medicines by 48.2% during the 4th quarter. Van ECK Associates Corp now owns 1,116 shares of the biotechnology company's stock worth $97,000 after purchasing an additional 363 shares during the last quarter.

Remove Ads

Blueprint Medicines Price Performance

BPMC traded down $1.01 during trading on Friday, hitting $88.72. The company's stock had a trading volume of 621,251 shares, compared to its average volume of 729,152. The company has a quick ratio of 2.80, a current ratio of 2.85 and a debt-to-equity ratio of 1.15. The stock has a market capitalization of $5.67 billion, a price-to-earnings ratio of -82.15 and a beta of 0.58. The firm's 50 day moving average price is $98.13 and its two-hundred day moving average price is $94.04. Blueprint Medicines Co. has a 12 month low of $80.68 and a 12 month high of $121.90.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last released its quarterly earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.11). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. Sell-side analysts forecast that Blueprint Medicines Co. will post -1.28 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have commented on BPMC shares. HC Wainwright reaffirmed a "buy" rating and issued a $135.00 price target on shares of Blueprint Medicines in a research report on Friday, February 14th. Stephens reissued an "overweight" rating and issued a $140.00 price target on shares of Blueprint Medicines in a report on Thursday, January 2nd. JMP Securities restated a "market outperform" rating and set a $125.00 price objective on shares of Blueprint Medicines in a report on Friday, February 14th. JPMorgan Chase & Co. lifted their target price on Blueprint Medicines from $126.00 to $129.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 4th. Finally, Jefferies Financial Group began coverage on Blueprint Medicines in a research note on Monday, March 17th. They set a "buy" rating and a $135.00 price target on the stock. Two analysts have rated the stock with a sell rating, six have issued a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, Blueprint Medicines has an average rating of "Moderate Buy" and a consensus price target of $124.95.

Insider Transactions at Blueprint Medicines

In other news, insider Ariel Hurley sold 3,203 shares of the company's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $92.62, for a total transaction of $296,661.86. Following the transaction, the insider now owns 18,270 shares of the company's stock, valued at $1,692,167.40. This represents a 14.92 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Kate Haviland sold 1,446 shares of the firm's stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $110.24, for a total value of $159,407.04. Following the completion of the transaction, the chief executive officer now owns 149,378 shares in the company, valued at approximately $16,467,430.72. This represents a 0.96 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 31,608 shares of company stock worth $3,319,587. Corporate insiders own 4.21% of the company's stock.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.